Burning Rock Gets CE Mark for Its OverC Multi-Cancer Detection Blood Test Kit

Shanghai, China-based Burning Rock Biotech has received a CE mark for its OverC multi-cancer detection blood test, which is manufactured in both U.S. and Chinese facilities.

The in vitro diagnostic test, which detects trace amounts of tumor-derived DNA methylation markers, can accurately detect and localize multiple cancer types in adults of either sex, aged 40 to 75.

The OverC test is based on Burning Rock's multi-cancer early detection technology ELSA-seq, which combines epigenetics, next-generation sequencing and machine learning.